The Wilms tumor gene wt1 and the protooncogene bcl-2 are upregulated in acute myeloid leukemia (AML) and are known to regulate or to inhibit the onset of apoptosis. Since wt1 has been shown to regulate the expression of bcl-2, we investigated the association of the expression of these genes and their prognostic relevance in AML. Leukemic blasts from the bone marrow of 152 patients with newly diagnosed AML were analyzed for bcl-2 and wt1 mRNA expression using RT-PCR and quantitative PCR. Therapy outcome was correlated with the level of bcl-2 and wt1 transcripts. Bcl-2-specific mRNA was detectable in 127/152 (84%) patients and wt1 mRNA in 113/152 (74%) patients with AML. In monocytic subtypes the frequency of bcl-2 and wt1 transcripts was significantly lower. The expression of bcl-2 mRNA was correlated significantly with that of wt1 mRNA (P Ͻ 0.0001). In AML patients Ͻ60 years, high expression of bcl-2 and wt1 was associated with a reduced rate of continuing complete remission (CCR, P = 0.002 and P = 0.005, respectively) and increased death rate (P = 0.0002 and P = 0.04, respectively) in contrast to patients Ͼ60 years, where the expression of bcl-2 or wt1 had no prognostic impact. Based on the coexpression of bcl-2 and wt1, we established a prognostic model defining three risk groups with significant differences in CCR rate (P = 0.01), overall survival (P Ͻ 0.04) and disease-free survival (P Ͻ 0.03). Thus, bcl-2 and wt1 mRNA expression are associated with response and long-term outcome in AMLs. The coexpression of these genes allows determination of prognostic groups with high predictive value for overall and disease-free survival. Leukemia (2002) 16, 846-854.
Introduction
The Wilms tumor gene (wt1) has been identified by deletion analysis of the 11p13 locus in Wilms tumors. 1, 2 Wt1 encodes a member of the Cys 2 -His 2 zinc finger family of transcription factors and is expressed in the developing urogenitary tract, mesothelial cells, brain and spleen.
3 Wt1 has been described as regulating the transcription of several growth factors and receptor genes (reviewed in Refs 4 and 5). Unlike most other transcription factors, wt1 protein is expressed in four different splicing variants with differences in DNA binding and biological functions. 6 Besides being a potent repressor of transcription, wt1 bears strong transactivating potential. [7] [8] [9] Due to the fact that cells of the metanephric blastema, which are required for normal kidney development, fail to proliferate and undergo apoptosis in wt1−/− knockout mice, an anti-apoptotic role of wt1 has been suggested. 10 Consistent with this hypothesis, wt1 was found to inhibit apoptosis by interacting directly with p53 and inhibiting p53-mediated apoptosis.
Since malignant transformation has been suggested as being influenced by a failure of apoptotic mechanisms, it is possible that the anti-apoptotic function of wt1 may potentiate tumorigenesis in cellular processes. Supporting this idea, wt1 has been found to be expressed in several malignant tissues including mesotheliomas, malignant melanomas, myeloid leukemias and a number of cell lines. 4, 5, 12, 13 In acute myeloid leukemias (AML), wt1 can be detected in the bone marrow of 70-80% of patients. [14] [15] [16] Its expression has been associated with an immature cell phenotype [17] [18] [19] and, as described by ourselves and others, with poor prognosis. 20, 21 Moreover, wt1 has been suggested to provide a cell survival function in tumor cells by overcoming proapoptotic signals and to be involved in leukemogenesis. 11, 22, 23 The physiological role of wt1 in non-malignant hematopoiesis as yet remains unclear. We could demonstrate that the expression of wt1 is expressed by a subpopulation of benign CD34
+ progenitors in the course of in vitro differentiation and subsequently downregulated during differentiation. 18 Furthermore, we found equal expression of wt1 in leukemic blasts from AML patients and in healthy progenitor cells, suggesting that the wt1 expression is related to malignant transformation rather by the persistence of its expression (lack of downregulation) than by overexpression. 24 Recently, wt1 was found to transcriptionally upregulate the protooncogene bcl-2 by activating the bcl-2 promoter through a high-affinity wt1 consensus site. 25 Moreover, Mayo et al 25 found that cells stably expressing the wt1 splice variant B had upregulated bcl-2 transcripts and protein and that cells coexpressing wt1 and bcl-2 are resistant to chemotherapyinduced apoptosis. Like wt1, the protooncogene bcl-2 has also been described to be involved in leukemogenesis and is known to be a prognostic factor in AML. [26] [27] [28] [29] [30] [31] Generally, in AML bcl-2 protein is present in about 87% at onset and in about 100% in the bone marrow of patients in relapse. 30 AML patients with high expression of bcl-2 mRNA or protein in leukemic blasts exhibit a poor response to chemotherapy. 29, 31 The in vitro chemosensitivity of AML cells to cytosine-arabinoside (Ara-C), the most active agent in AML therapy, can be increased by bcl-2 downregulation by antisense oligonucleotides, all-trans retinoic acid (ATRA), interleukin 6 or G-CSF. [32] [33] [34] On the other hand, retroviral transfection of bcl-2 into human leukemic cell lines reduced the susceptibility of cells to cytotoxic agents. 35 These data suggest that bcl-2 plays a significant role in the drug resistance of AML cells and contributes to an unfavorable prognosis. [27] [28] [29] 31, 32, 35, 36 In agreement with the reported transcriptional regulation of bcl-2 by wt1 in vitro, 25 this is the first study, to our knowledge, reporting a positive correlation of both genes in primary cells and a prognostic relevance of the coexpression of wt1 and bcl-2 in AML.
Materials and methods

Patients and materials
This study included 152 consecutive patients with newly diagnosed AML, 147 patients were evaluable for response and follow-up, in three patients it was too early for evaluation and two patients refused treatment. The diagnosis was performed according to morphological and cytochemical criteria of the French-American-British (FAB) study group. 37 Cytogenetics were available in 78 of the 152 patients studied.
The treatment schedule for newly diagnosed AMLs consisted of induction and early consolidation courses with a combination of cytosine-arabinoside (AraC), etoposide and an anthracycline (daunorubicine or idarubicine). 38 Patients with age Ͻ50 years received a late consolidation therapy with a high-dose AraC regimen, those with age Ͼ50 years received an intermediate-high-dose AraC regimen. Patients with promyelocytic leukemia (AML FAB M3) received a special chemotherapy protocol including all-trans retinoic acid. Informed consent according to the criteria of the local ethical commission was required for participation.
RNA isolation and PCR
To analyze blast cells for the expression of bcl-2 and wt1 mRNA, fresh heparinized bone marrow was recovered at the time of diagnosis. Patients with inaspirarable bone marrow were excluded from the study. After density gradient sedimentation using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden), the samples were washed twice in phosphate-buffered saline and used for RNA extraction.
Total RNA was prepared according to the technique published by Chomczynski and Sacchi 39 using the RNAzol B method (Biotex, Houston, TX, USA). After purification, total RNA was redissolved in diethylpyrocarbonate-treated water and aliquots of 5 g total RNA were reverse transcribed into cDNA as described. 20 All reagents were purchased from Gibco/BRL (Berlin, Germany).
Polymerase chain reaction (PCR) was performed as described previously 40 and according to the instructions of the manufacturer. Oligonucleotides specific for bcl-2 and wt1 mRNA annealing in the coding region and spanning one intron to exclude DNA contamination were synthesized as follows (wt1 5Ј-primer: 5Ј-ATGAGGATCCCATGGGCCAGCA; wt1 3Ј-primer: 5Ј-CCTGGGACACTGAACGGTCCCCGA; bcl-2 5Ј-primer: 5Ј-CCGCTACCGCCGCGACTTC; bcl-2 3Ј-primer: 5Ј-AAACAGAGGCCGCATGCTG). Amplifications of bcl-2 and wt1 cDNA were performed with 35 cycles under the following conditions. The cycles were initiated by denaturing the DNA at 94°C for 30 s, followed by an annealing reaction for 30 s at 64°C and extending at 72°C for 45 s. After the last cycle, a final extension reaction at 72°C for 7 min was performed.
To estimate the integrity and amount of cDNA, the ␤-actin gene was amplified as an internal control (5Ј-primer: 5Ј-AGCAAGAGAGGCATCCTGACC; 3Ј-primer: 5Ј-CTTCA TGATGGAGTTGAAGGTAG). Each PCR included a negative and a positive control with cDNA derived from the wt1 expressing cell line HEL 92.1.7 and the bcl-2 expressing cell line KG1, respectively. Amplification products were separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining. The ethidium bromide stained and photographed Leukemia amplification product was visually classified as not amplified (−), weakly (+), moderately (++) and strongly (+++) amplified as described previously. 15, 20 Quantitative PCR A competitive template serving as an internal standard for quantitation of wt1 mRNA was designed as previously described. 20, 41 PCR of the shortened clone yielded a band of 706 bp compared to 851 bp using wild-type wt1 as template, allowing products to be distinguished after amplification in the same PCR reaction. Southern blots were performed to quantitate PCR products as well as to ensure their integrity, as described. 42 The internal standard for bcl-2 was constructed by PCR. A 3Ј-primer annealing 81 bp upstream of the 3Ј-primer site for bcl-2 PCR was designed with the sequence of the normal primer site (as above) linked at the 5Ј end as described before 29 (bcl-2 internal standard 3Ј-primer 5Ј-AACAGA GGCCGCATGCTG-CCGGTTCAGGTACTCAGTCAT-3Ј. The PCR product obtained by using this primer was cloned into pT7Blue (Novagen, Abingdon, UK). PCR amplification of this construct with the normal bcl-2 primer pair resulted in a shortened product (251 bp) providing an internal standard for the competitive PCR.
After ␤-actin normalization, sample cDNA was amplified together with 3 l standard cDNA containing 0.04 fg/l, 0.4 fg/l, 4 fg/l, 40 fg/l, 400 fg/l, 4000 fg/l, respectively. PCR conditions were the same as described above. PCR products were separated on a 2% agarose gel and subsequently blotted.
In order to determine the exact amount of wt1 or bcl-2-specific mRNA, the decadic logarithm of the quotient of volume of the sample and the standard was plotted against the decadic logarithm of the amount of standard RNA. Linear regression analysis was performed. At the point of intersection with the X-axis, the ratio equaled 1, the amount of standard and of the sample were identical.
Statistics
Overall survival (OS) was calculated from diagnosis until death, disease-free survival (DFS) from time of complete remission (CR) until relapse. The survival curves were estimated by the Kaplan-Meier method. The log-rank test was used to assess the significance of difference in survival. Fisher's exact test was used to analyze contingency tables of response in association with bcl-2 and wt1 mRNA expression.
All P values were two-sided and were considered significant when less than 0.05.
Additionally, performing a multivariate Cox regression analysis, all relevant variables (bcl-2, wt1, sex, age, white blood cell count) were included in a stepwise procedure (nonquantitative variables were substituted by dummy variables.)
Results
Expression of bcl-2 mRNA and wt1 mRNA in acute myeloid leukemias
Total mRNA of bone marrow from 152 patients with newly diagnosed AML (116 patients with de novo AML, 36 with antecedent MDS) was analyzed for bcl-2-and wt1-specific transcripts. The median age was 53 years (17-82); 102 patients (67%) were younger than 60 years. One hundred and forty-seven of all patients and 98 of those р60 years were evaluable for response.
In 127 patients (84%), bcl-2 mRNA was detectable by RT-PCR (Table 1, Figure 1 ). One hundred and two of 116 patients with de novo AML (88%) expressed bcl-2 mRNA in contrast to 25/36 patients with AML following MDS (69%; P = 0.02). Additionally, the frequency of bcl-2 mRNA expression was significantly lower in monocytic (FAB M4 and M5) subtypes than in others (80% vs 94%, P = 0.04; Table 1 ).
Transcripts of the Wilms tumor gene wt1 were detected in 74% (113/152) of the patients without a difference concerning age, antecedent MDS and FAB classification with the exception of M5 leukemias, which expressed wt1 mRNA in only 50% compared to 77% in all other de novo AMLs (P = 0.05; Table 1 ).
There was no difference in the frequency of bcl-2 or wt1 transcripts concerning age, sex, white blood count or bone marrow cellularity (Table 1) . With regard to the cytogenetic analyses, which were available in 78 patients, there were no significant differences in the frequency of bcl-2 or wt1 expression concerning favorable aberrations such as t(15;17), t(8;21) and inv (16) or unfavorable or normal cytogenetic findings (Table 1) .
Correlation of the bcl-2 and wt1 mRNA expression
The quantitative PCR (Figure 2 ) revealed that the (+) classified PCR products corresponded to 0.09 fg (± 0.11) RNA out of 1 g total RNA for wt1 and 77 fg (± 35.3) RNA for bcl-2, the (++) to 0.85 fg (± 0.45) and 6.9 pg (± 3.6), and the (+++) to 8.92 fg (± 7.8) and 45 pg (± 14.2), for wt1 and bcl-2 mRNA, respectively. The bcl-2-and wt1-specific mRNA contents were about 1-2 log10 higher in moderately and strongly 
Figure 2
Quantitative PCR products using a competitor template serving as an internal standard run on a 2% agarose gel. Equal amounts of sample RNA were amplified together with 0. amplified products than in the others. Therefore, AMLs with no or weakly detectable bcl-2 or wt1 signals and those with moderate and strong wt1 levels were summarized as one group each for survival analyses.
Using the Fisher's exact test a significant correlation of the intensity of the expression of wt1 and bcl-2 mRNA was found (P Ͻ 0.0001). Most of the samples with undetectable bcl-2 mRNA lacked wt1 mRNA expression, whereas the majority with strong expression of bcl-2 mRNA showed high wt1 mRNA levels ( Figure 3) .
Influence of the expression of bcl-2 and wt1 mRNA on therapy response and long-term outcome
One hundred and forty-seven of the 152 patients were evaluable for response. The median observation time was 31 months (3+-63+). Ninety-seven (66%) of the 147 patients achieved a CR following chemotherapy ( Table 2 ). The probability of 1-, 3-and 5-year OS was 46%, 25% and 25%, respectively. Forty-three complete responders (44%) relapsed after a median time of 7 months (1-20) resulting in a DFS of 58%, 38% and 38% after 1, 3 and 5 years for CR patients, respectively. Patients who underwent bone marrow or stem cell transplantation were censored at time of transplantation.
Leukemia
bcl-2 expression and therapy outcome:
Fifty-three (62%) of 86 patients with high expression of bcl-2 mRNA achieved CR, compared to a CR rate of 72% in bcl-2-negative and low expressing cases (Table 2) . Twenty-seven patients (51%) of the 53 complete responders relapsed compared to 36% of those with no or low expression of bcl-2 mRNA (Table 2) . Concerning patients Ͻ60 years, the rate of complete remission and continuing complete remission (CCR) was significantly lower in patients with high bcl-2 expression (P = 0.001 and P = 0.002, respectively, Table 2 ). The death rate was significantly higher in those patients (P = 0.0002).
In de novo AML, 82% (36/44) of bcl-2-negative or low expressing patients achieved CR compared to 42/72 (58%) AML patients with high expression (P Ͻ 0.02). In AML patients with antecedent MDS, there was no significant correlation between the level of bcl-2 expression and CR rate.
wt1 expression and therapy outcome:
Concerning the expression of the Wilms tumor gene wt1, undetectable and low levels of wt1 mRNA correlated with a high CCR rate (46%) compared to 26% in strongly wt1-positive patients (P Ͻ 0.02). In patients р60 years the statistical difference was more obvious concerning the CCR rate (60% vs 31%, P = 0.005) and the death rate (34% vs 56%, P = 0.04).
Strong expression of bcl-2 or wt1 was associated with the highest relapse and death rate compared to the patients with undetectable or weak RNA expression (Table 2) . With regard to the OS and DFS, patients with no or low expression of bcl-2 or wt1, respectively, had a better long-term outcome compared to patients with high expression (Figure 4 ).
Cox regression analysis:
Using a multivariate Cox regression analysis, the variables (bcl-2, wt1, sex, age, white blood cell count) were included in a stepwise procedure (nonquantitative variables were substituted by dummy variables.) However, only patient's age was identified as a significant predictor of survival (P = 0.018) in this analysis.
Prognostic model based on the coexpression of bcl-2 and wt1 mRNA
With regard to the unfavorable prognosis of AML patients with high expression of bcl-2 or wt1 mRNA, we assumed that patients with high expression of both genes might have a worse long-term outcome compared to those with no or low expression of bcl-2 and wt1 mRNA. Based on this assumption we postulated a prognostic model with a low, intermediate and high risk group (Table 3 ). The characteristics of the analyzed patients according to these risk groups are listed in Table 4 .
Generally, there were no significant differences in the three risk categories concerning age or FAB classification with the exception of promyelocytic leukemias (AML M3), which were predominantly found in the intermediate risk group. With regard to cytogenetics the distribution of the different prognostic groups defined by karyotyping was statistically not significant (Table 4) . Merely, it was noticeable that about 56% of the patients with favorable karyotype were found in the intermediate risk group.
To evaluate the relevance of the bcl-2 and wt1 mRNAbased prognostic model, we investigated the therapy response and long-term outcome of the 147 patients according to risk groups. While there was no significance concerning complete remission, the rate of continuing complete remission (CCR) was significantly higher in patients with low risk (51%) compared to intermediate risk (36%) and high risk (24%, P = 0.01, Table 4 ). With regard to OS, a significantly better long-term outcome was seen in patients with low risk attaining a plateau at 50% after 18 months with a high percentage of long-term survivors compared to those with intermediate and high risk (P Ͻ 0.04, Figure 5 ). Patients with intermediate risk had a 20% probability for 3-year OS, while only one patient with high risk survived longer than 2 years. Analyzing the OS of patients р60 years (n = 98), the discrimination of prognostic groups was more obvious with a probability of 3-year OS with 67% for patients with low risk and 41% and 0% for intermediate and high risk patients (P Ͻ 0.0029, Figure 5 ). The different prognostic groups defined by bcl-2 and wt1 expression were also reflected by significant differences in DFS of the 97 CR patients showing a significantly shorter remission duration for patients with high risk compared to patients with intermediate or low risk (P Ͻ 0.03, Figure 6 ). The probability of DFS after 3 years was 60%, 38% and 0% in the three different risk groups. The difference concerning the DFS again was even more significant in patients Ͻ60 years (P = 0.0023, Figure 6 ).
Discussion
Mayo et al 25 described wt1 as transcriptionally upregulating the apoptosis-inhibiting protooncogene bcl-2 by activating the bcl-2 promoter. 25 Therefore, wt1 expressing cells displayed an extreme resistance to pro-apoptotic agents such as vincristine, doxorubicine and staurosporine 25 confirming the suggested anti-apoptotic function of wt1. 11, 22 With regard to the transcriptional activation of bcl-2 by wt1, we decided to investigate the association of the expression of both these genes in AML. In agreement with the results of Mayo et al, 25 we found a highly significant positive correlation between the levels of bcl-2 and wt1 transcripts in leukemic blasts of AML patients (P Ͻ 0.0001) indicating an upregulation of bcl-2 by wt1 in AML.
Recently, the expression of bcl-2 or wt1 has been independently demonstrated to be prognostically relevant for the longLeukemia term outcome of AML patients. 20, 21, 28, 29, 31 Recently, we 20 and Inoue et al 21 have shown that the level of wt1 mRNA expression is significantly associated with the long-term outcome of patients with AML. High transcription levels predict a slightly reduced CR rate as well as a significantly worse DFS and OS. Generally, our data confirm the recently published results concerning the frequency and the prognostic significance of wt1 mRNA expression in AML. 21 It is worth mentioning that Schmid et al 43 did not find any correlation between wt1 expression and therapy response or survival. Additionally, our results indicate that besides bcl-2 protein expression 28, 31 high levels of bcl-2 transcripts, too, are associated with a worse prognosis concerning CR rate, DFS and OS. Interestingly, in secondary AML the expression of bcl-2 was significantly lower than in de novo AML and was not correlated with prognosis, confirming previous data. 28, 44 The pathophysiological relevance of wt1 in AML and its involvement in leukemogenesis is underscored by the data of Yamagami et al, 23 who showed that leukemic growth was inhibited in vitro by the reduction of wt1 protein via wt1 antisense oligomers. Moreover, Algar et al 22 proposed normal wt1 protein to be necessary for cell proliferation and to play a role in maintaining the viability of leukemic cells. Confirming the assumption that wt1 performs an oncogenic rather than a tumor-suppressor gene function in leukemias is the observation that wt1 expression levels are significantly correlated with disease progression and transformation of myelodysplastic syndromes to AML and the chronic phase of chronic myeloid leukemia to blast crisis, respectively. 14, 45, 46 Another explanation for the prognostic impact of wt1 is provided by the transcriptional activation of the bcl-2 gene by wt1, 25 its involvement in the inhibition of apoptosis induced by cytostatic agents 25 and the correlated expression of wt1 and the multidrug resistance gene mdr-1 in chemotherapy resistant cell lines. [32] [33] [34] [35] [36] 47 Despite the strong correlation of the levels of bcl-2 and wt1 transcripts, elevated transcription levels of only one gene contribute to a worse prognosis, indicating also possible independent pathways or only a final common pathway. In this context, it is of interest that bcl-2 and wt1 interact with the tumor suppressor gene p53 and its ability to induce apoptosis. P53 is known to downregulate bcl-2 in vitro and in vivo.
48
Wt1 protein is described as stabilizing p53 modulating its transactivational properties and consecutively inhibiting its function.
11
Based on the present study, we postulated a new prognostic model discriminating three risk groups. Patients with high coexpression of bcl-2 and wt1 defined as high risk had a significantly worse long-term outcome with no patient surviving 3 years compared to a probability for 3-year OS of 33% in intermediate risk and 56% in low risk patients (P = 0.04). Similarly significant differences were found for the DFS and CR rate of these three risk groups. The significance increased after exclusion of AML cases with preceding MDS whose prognosis was not correlated to bcl-2 or wt1 expression. Additionally, it is noteworthy that the proposed model has no prognostic impact in patients Ͼ60 years concerning remission rate or survival. This may be caused by the recently discussed different biological characteristics of de novo AML of young people and the AML of the elderly, 49 which seem to be more related to AML following MDS. As mentioned above, in this patient group the proposed model has no prognostic relevance either.
We performed a multivariate Cox regression analysis and by including the parameters age, sex, white blood cell count, cytogenetics and bcl-2 and wt1 expression we found only age to be a significant predictor for length of survival. This might be due to the limited number of analyzed patients, available cytogenetics and to heterogeneous factors of the disease biology in elderly patients, leading to an unfavorable prognosis. However, the Cox regression analysis revealed the prognostic model based on the combination of the expression of bcl-2 and wt1 to be independent of sex, age, white blood cell count and especially cytogenetics.
Although even the high expression of only one gene is associated with a worse prognosis, the predictive value for the overall and DFS is increased by combining the expression of bcl-2 and wt1 in this proposed prognostic model. Interestingly, the survival curves between the three risk groups did not differ within the first year following diagnosis. As there are significant differences in the DFS of CR patients, the data indicate that the long-term prognosis was not reflected by the initial response to chemotherapy in relation to the bcl-2 and wt1 mRNA expression. The differences in OS and DFS in relation to this prognostic model are predominantly contributed to by late relapses. These data suggest that drug-resistant subclones may represent the source for following relapse emerging from bcl-2 and/or wt1 high expressing subpopulations. Such intraclonal heterogeneity for bcl-2 expression has been postulated by Porwit-MacDonald et al 50 and has been also observed in some of our patients for bcl-2 protein (data not shown). In this context it has to be pointed out that both genes are detected more frequently and with higher mRNA levels in the case of AML relapses. 51 This may be due to a higher relapse rate of patients with high expression of bcl-2 or wt1 or is reflecting a clonal selection of more resistant leukemic blasts exhibiting high expression of both genes.
Currently, the discrimination of different prognostic groups by karyotyping is the most appropriate risk factor in AML. The various cytogenetic aberrations, however, do not generally reflect the biological relevance of these findings especially in regard to possible resistance to cytotoxic agents.
In conclusion, the expression of bcl-2 and wt1 mRNA is significantly correlated in leukemic blasts and is associated with the long-term outcome in patients with AML. Based on the coexpression of these genes it is possible to establish a prognostic model defining three risk groups in AML. Its relevance has to be elucidated by further ongoing studies.
